{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:50:45Z","timestamp":1790819445316,"version":"4.1.0"},"reference-count":15,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,10]]},"abstract":"<jats:p> PURPOSE: To determine the side effects of and response to pentostatin in patients with T-cell lymphomas with cutaneous manifestations. <\/jats:p><jats:p> PATIENTS AND METHODS: Pentostatin was administered to 28 patients who had relapsed cutaneous T-cell lymphoma or peripheral T-cell lymphoma with prominent cutaneous disease. The starting dose was between 3.75 to 5.0 mg\/m<jats:sup>2<\/jats:sup>\/d intravenous for 3 days every 3 weeks. <\/jats:p><jats:p> RESULTS: Of the 24 patients assessable for response, 17 (71%) achieved a partial remission (46%) or complete remission (25%). The patients had a median number of three (range, one to 12) prior therapies. Of the 86 courses of pentostatin given, 39 were administered at doses of 5.0 mg\/m<jats:sup>2<\/jats:sup>\/d and 30 at doses of 3.75 mg\/m<jats:sup>2<\/jats:sup>\/d. Dose escalation to 6.25 mg\/m<jats:sup>2<\/jats:sup>\/d was possible in only five courses, and toxicity necessitated dose reduction to 2.8 mg\/m<jats:sup>2<\/jats:sup>\/d in 12 courses. The most common side effects were granulocytopenia, nausea, and nonneutropenic fever. Most patients developed significant lowering of CD4 counts. Herpes zoster was seen within 1 year after pentostatin in five patients (19%). <\/jats:p><jats:p> CONCLUSION: Pentostatin is an active agent in heavily pretreated T-cell lymphomas with cutaneous manifestations. <\/jats:p>","DOI":"10.1200\/jco.1999.17.10.3117","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:56:34Z","timestamp":1487919394000},"page":"3117-3121","source":"Crossref","is-referenced-by-count":87,"title":["Pentostatin Therapy of T-Cell Lymphomas With Cutaneous Manifestations"],"prefix":"10.1200","volume":"17","author":[{"given":"Razelle","family":"Kurzrock","sequence":"first","affiliation":[{"name":"From the Departments of Bioimmunotherapy and Medical Specialties, University of Texas, M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Pilat","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy and Medical Specialties, University of Texas, M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy and Medical Specialties, University of Texas, M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-3117","unstructured":"Willemze  R,  Kerl  H,  Sterry  W, et al: EORTC classification for primary cutaneous lymphomas: A proposal from the cutaneous lymphoma study group of the European organization for research and treatment of cancer.  Blood 90:354,1997-371,"},{"key":"R2-3117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"R3-3117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2385.bloodjournal8872385"},{"key":"R4-3117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V57.3.406.bloodjournal573406"},{"key":"R5-3117","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870815)60:4<750::AID-CNCR2820600407>3.0.CO;2-1"},{"key":"R6-3117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V58.1.91.bloodjournal58191"},{"key":"R7-3117","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1991.423"},{"key":"R8-3117","unstructured":"Cummings  FJ,  Tsiatis  A,  O'Connell  M, et al: Phase II trial of low dose 2-deoxycoformycin in refractory malignant lymphomas.  Proc Am Assoc Cancer Res 27:197,1986,  (abstr)"},{"key":"R10-3117","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80279-4"},{"key":"R11-3117","doi-asserted-by":"crossref","unstructured":"Lamberg  SI,  Green  S,  Byar  D, et al: Clinical staging for cutaneous T-cell lymphoma.  Ann Intern Med 100:187,1994-191,","DOI":"10.7326\/0003-4819-100-2-187"},{"key":"R12-3117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198702053160603"},{"key":"R13-3117","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199346040-00006"},{"key":"R14-3117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704023161401"},{"key":"R15-3117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.12.4061.bloodjournal84124061"},{"key":"R16-3117","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400513"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.10.3117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:34:33Z","timestamp":1653514473000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.10.3117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["10.1200\/JCO.1999.17.10.3117"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.10.3117","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,10]]}}}